Tumor Biology

, Volume 37, Issue 6, pp 7915–7920 | Cite as

MicroRNA-148a represents an independent prognostic marker in bladder cancer

  • Lin Ma
  • Zhishun Xu
  • Chao Xu
  • Xianzhou Jiang
Original Article


A previous study has demonstrated the roles of microRNA-148a (miR-148a) on apoptosis of bladder cancer cells. The goal of this study was to investigate whether the miR-148a expression level could serve as a new biomarker for the prognosis of bladder cancer patients. We collected a total of 126 bladder cancer samples. The expression level of miR-148a was determined with quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan-Meier method was used to analyze the overall survival. Cox regression analysis was further used to identify prognostic factors. The expression levels of miR-148a in bladder cancer tissues were identified (1.5 ± 0.3; P < 0.001). The bladder cancer patients in the low-expression group more frequently had a high tumor grade (P = 0.025), increased tumor recurrence (P = 0.002), and advanced lymph node (LN) metastasis (P = 0.001). Patient survival analysis revealed a clear positive correlation between miR-148a expression level and survival time of bladder cancer patients (P = 0.005, log-rank = 7.714). In univariate Cox proportional hazards regression analysis, we found that a low-expression level of miR-148a (P = 0.018), tumor grade (P = 0.006), lymph node metastasis (P = 0.001), and recurrence (P < 0.001) were associated with the prognosis of bladder cancer. In multivariate analysis, we found that miR-148a expression (RR = 0.206, 95 % CI 0.095–0.813, P = 0.029), tumor grade (RR = 0.714, 95 % CI 0.224–0.958, P = 0.714), lymph node metastasis (RR = 6.604, 95 % CI 3.192–12.547, P < 0.001), and recurrence (RR = 15.126, 95 % CI 6.714–22.025, P < 0.001) retained significance as an independent prognostic factor of bladder cancer survival (Table 3). All results have showed that miR-148a expression was decreased in bladder cancer specimens and reduced miR-148a expression was associated with poorer survival time, indicating that miR-148a may become a candidate factor for predicting the prognosis of bladder cancer.


miR-148a Bladder cancer Survival Prognosis 


Compliance with ethical standards

This study was approved by the Ethics Review Board of Qilu Hospital affiliated to Shan Dong University. Informed consent was obtained from each participant.

Conflicts of interest





  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011;18:e25–34.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (ms-snupe). Nucleic Acids Res. 1997;25:2529–31.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pliarchopoulou K, Laschos K, Pectasides D. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol Oncol. 2013;31:294–302.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim JJ. Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep. 2012;13:147–52.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Verdoorn BP, Kessler ER, Flaig TW. Targeted therapy in advanced urothelial carcinoma. Oncology (Williston Park). 2013;27:219–26.Google Scholar
  8. 8.
    Andrew AS, Marsit CJ, Schned AR, Seigne JD, Kelsey KT, Moore JH, et al. Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence. Int J Cancer. 2014;137(5):1158–66.CrossRefGoogle Scholar
  9. 9.
    Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102–14.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, et al. Elevated expression of mir-210 predicts poor survival of cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9:e89223.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010;46:2295–303.CrossRefPubMedGoogle Scholar
  12. 12.
    Li P, Mao WM, Zheng ZG, Dong ZM, Ling ZQ. Down-regulation of PTEN expression modulated by dysregulated miR-21 contributes to the progression of esophageal cancer. Dig Dis Sci. 2013;58:3483–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang Y, et al. MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci. 2013;9:680–92.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther. 2013;12:2569–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Yao K, He L, Gan Y, Zeng Q, Dai Y, Tan J. Mir-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1. Diagn Pathol. 2015;10:146.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yang Y, Qu A, Liu J, Wang R, Liu Y, Li G, et al. Serum miR-210 contributes to tumor detection, stage prediction and dynamic surveillance in patients with bladder cancer. PLoS One. 2015;10:e0135168.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lei M, Xie W, Sun E, Sun Y, Tian D, Liu C, et al. MicroRNA-21 regulates cell proliferation and migration and cross talk with PTEN and p53 in bladder cancer. DNA Cell Biol. 2015;34(10):626–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Yu G, Xu K, Xu S, Zhang X, Huang Q, Lang B. microRNA-34a regulates cell cycle by targeting CD44 in human bladder carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35:935–40.PubMedGoogle Scholar
  19. 19.
    Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57:840–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Li J, Song Y, Wang Y, Luo J, Yu W. MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 2013;380:277–82.CrossRefPubMedGoogle Scholar
  21. 21.
    Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17:7574–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee SK, et al. MicroRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. Oncotarget. 2014;5:2792–806.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zuo J, Xia J, Ju F, Yan J, Zhu A, Jin S, et al. MicroRNArna-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer. Mol Cell. 2013;35:313–9.CrossRefGoogle Scholar
  24. 24.
    Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, et al. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 2013;32:3246–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, et al. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Investig. 2011;91:1472–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011;18:1702–10.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yu J, Li Q, Xu Q, Liu L, Jiang B. MiR-148a inhibits angiogenesis by targeting ERBB3. J Biomed Res. 2011;25:170–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yan H, Dong X, Zhong X, Ye J, Zhou Y, Yang X, et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog. 2014;53:960–9.PubMedGoogle Scholar
  29. 29.
    Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM, Mudryj M: Mir-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier dnmt1. Mol Carcinog 2015Google Scholar
  30. 30.
    Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123:630–45.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Zhang R, Li M, Zang W, Chen X, Wang Y, Li P, et al. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour Biol. 2014;35:837–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008;105:13556–61.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Shivapurkar N, Weiner LM, Marshall JL, Madhavan S, Deslattes Mays A, Juhl H, et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One. 2014;9:e84686.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Aydogdu E, Katchy A, Tsouko E, Lin CY, Haldosen LA, Helguero L, et al. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis. 2012;33:1502–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285:19076–84.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36:3035–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Ajdarkosh H, Dadpay M, Yahaghi E, Pirzaman ER, Fayyaz AF, Darian EK, et al. Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues. Diagn Pathol. 2015;10:135.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of UrologyQilu Hospital of Shan Dong UniversityJinan CityChina
  2. 2.Department of UrologyReproductive Hospital Affiliated to Shandong UniversityJinanChina

Personalised recommendations